The HAQ disability index in scleroderma trials [8]

Rheumatology

Volumn 43, Issue 9, 2004, Pages 1200-1201

  Johnson, Sindhuj R ^b,c   Lee, P ^a  

^a UNIVERSITY OF TORONTO   (Canada)

^b UNIVERSITY HEALTH NETWORK   (Canada)

^c TORONTO WESTERN HOSPITAL   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

BIOLOGICAL FACTOR; RHEUMATOID FACTOR;

BIOLOGICAL THERAPY; BONE EROSION; COHORT ANALYSIS; CONSERVATIVE TREATMENT; DISEASE ACTIVITY; DISEASE DURATION; DISEASE SEVERITY; HUMAN; LETTER; MEDICAL ASSESSMENT; PATIENT SELECTION; PREDICTION; PRESCRIPTION; PRIORITY JOURNAL; QUESTIONNAIRE; RHEUMATOID ARTHRITIS; SERODIAGNOSIS; STATISTICAL SIGNIFICANCE;

DISABILITY EVALUATION; HEALTH STATUS INDICATORS; HUMANS; SCLERODERMA, DIFFUSE;

EID: 4544264625     PISSN: 14620324     EISSN: None     Source Type: Journal    
DOI: 10.1093/rheumatology/keh288     Document Type: Letter

References (12)

1. Sultan N, Pope JE, Clements PJ. The health assessment questionnaire (HAQ) is strongly predictive of good outcome in early diffuse scleroderma: results from an analysis of two randomized controlled trials in early diffuse scleroderma. Rheumatology 2004;43:472-8.
2. Fries JF, Spitz PW, Young DY. The dimensions of health outcomes: the health assessment questionnaire, disability and pain scales. J Rheumatol 1982;9:789-93.
3. Poole JL, Steen VD. The use of the Health Assessment Questionnaire (HAQ) to determine physical disability in systemic sclerosis. Arthritis Care Res 1991;4:27-31.
4. Smyth AE, MacGregor AJ, Mukerjee D, Brough GM, Black CM, Denton CP. A cross-sectional comparison of three self-reported functional indices in scleroderma. Rheumatology 2003;42:732-8.
5. Clements PJ, Wong WK, Hurwitz EL et al. Correlates of the disability index of the health assessment questionnaire: a measure of functional impairment in systemic sclerosis. Arthritis Rheum 1999; 42:2372-80.
6. Moser DK, Clements PJ, Brecht ML, Weiner SR. Predictors of psychosocial adjustment in systemic sclerosis. The influence of formal education level, functional ability, hardiness, uncertainty, and social support. Arthritis Rheum 1993;36:1398-405.
7. Fries JF, Spitz P, Kraines RG, Holman HR. Measurement of patient outcome in arthritis. Arthritis Rheum 1980;23:137-45.
8. Wolfe F. The determination and measurement of functional disability in rheumatoid arthritis. Arthritis Res 2002;4(Suppl. 2): S11-5.
9. Bruce B, Fries JF. The Stanford Health AssesTment Questionnaire: a review of its history, issues, progress, and documentation. J Rheumatol 2003;30:167-79.
10. Clements PJ, Furst DE, Wong WK et al. High-dose versus low-dose D-penicillamine in early diffuse systemic sclerosis: analysis of a two-year, double-blind, randomized, controlled clinical trial. Arthritis Rheum 1999;42:1194-203.
11. Pope JE, Bellamy N, Seibold JR et al. A randomized, controlled trial of methotrexate versus placebo in early diffuse scleroderma. Arthritis Rheum 2001;44:1351-8.
12. Seibold JR, Korn JH, Simms R et al. Recombinant h,-iman relaxin in the treatment of scleroderma. A randomized. double-Mind, placebo-controlled trial. Ann Intern Med 2000;132:871-9.